Objective: This study was undertaken to characterize the pharmacokinetics of zidovudine (ZDV) and ZDV-glucuronide (ZDVG) in the material and fetal circulations of the rhesus monkey.
n the United States there are an estimated 6,000 pregnancies annually in women who are human immunodeficiency virus (HIV) positive. Treatment with zidovudine (ZDV) is recommended for non-pregnant HIV-infected individuals whose CD4 cell counts drop below 500/mm3. 2 In the pregnant patient, treatment with ZDV is not specifically recommended until the CD4 cell count drops below 200/mm3. 3 Some feel ZDV treatment should be offered during pregnancy when CD4 counts drop below 500/mm3. 3 Regardless of when treatment is initiated, it is apparent that an increasing number of pregnant women and their fetuses are being exposed to ZDV. 4 While there is considerable information on the pharmacology and metabolism of ZDV in men, there are limited data on the pharmacokinetics of ZDV in the pregnant mother and her fetus.
Hankins et al. 5 examined maternal, fetal, and amniotic fluid levels of ZDV and ZDV-glucuronide (ZDVG) after multiple oral doses in near Figure  3 shows the maternal and fetal concentrations of ZDVG in animals who received ZDVG. Table 1 shows the fetal/maternal ratio over the sampling interval for the animals given ZDV and ZDVG. If the serum concentration in the numerator or denominator was zero, the time value was not used in the calculation of the ratios. Tables 2 and 3 summarize the pharmacokinetic parameter estimates for ZDV and ZDVG. In animals receiving ZDVG, complete data were not obtained in monkey 3 for maternal levels after the first dose and the fetal levels after the second dose. Other placental metabolites of AZT have been reported 8'9 and were not sought in this study.
In the animals receiving ZDV, the maternal and fetal T1/2 for ZDVG were significantly longer than for ZDV (P < 0.016). Peak [14] [15] [16] Moreover, the rapid clearance of ZDVG from the maternal circulation and the slower transfer of ZDVG across the placenta probably contribute to the retention of this metabolite in the fetus and the increased fetal/maternal ratio. Other investigators 5 have reported high levels of ZDVG in fetal serum and amniotic fluid of pregnant monkeys given multiple oral doses of ZDV and have proposed that the amniotic fluid may serve as a reservoir for ZDVG. Verification of this overall concept will require infusions of both ZDV and ZDVG into the fetal compartment with monitoring of relative rates of transfer of each substance into the maternal circulation and into fetal bile and urine (amniotic fluid). Preliminary data in our unit, however, using the perfused isolated placental cotyledon support a more rapid diffusion of ZDV than of ZDVG across the human placenta. This is consistent with the greater polarity of ZDVG 8'9 and with the concept that these drugs cross the placenta passively. [8] [9] [10] While transfer of animal data to clinical medicine is difficult, our data suggest that ZDV dosing does not need to be modified in pregnancy as ZDV should not accumulate in the fetal compartment. While ZDVG may accumulate in this compartment, this should not be clinically important as long as the metabolite remains inactive.
In conclusion, our data along with those of the previously cited investigators suggest that both ZDV 
